Chemocentryx Drug Patent Portfolio
Chemocentryx owns 1 orange book drug protected by 4 US patents Given below is the list of Chemocentryx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11603356 | Amorphous form of a complement component C5a receptor | 29 May, 2041 | Active |
| US11951214 | Capsule formulations | 27 Nov, 2039 | Active |
| US8445515 | C5aR antagonists | 03 Feb, 2031 | Active |
| US8906938 | C5aR antagonists | 21 Dec, 2029 | Active |
Latest Legal Activities on Chemocentryx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Chemocentryx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Apr, 2024 | US11951214 |
|
Email Notification
Critical
| 16 Apr, 2024 | US11951214 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Apr, 2024 | US8906938 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Apr, 2024 | US8445515 |
|
Email Notification
Critical
| 12 Apr, 2024 | US8906938 |
|
Email Notification
Critical
| 12 Apr, 2024 | US8445515 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951214 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951214 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11951214 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951214 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
|
Email Notification
Critical
| 03 Apr, 2024 | US11603356 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Apr, 2024 | US11603356 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11951214 |
Chemocentryx's Family Patents
Chemocentryx Drug List
Given below is the complete list of Chemocentryx's drugs and the patents protecting them.
1. Tavneos
Tavneos is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11603356 | Amorphous form of a complement component C5a receptor |
29 May, 2041
(16 years from now)
| Active |
| US11951214 | Capsule formulations |
27 Nov, 2039
(14 years from now)
| Active |
| US8445515 | C5aR antagonists |
03 Feb, 2031
(6 years from now)
| Active |
| US8906938 | C5aR antagonists |
21 Dec, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tavneos's drug page